贝伐单抗治疗非鳞癌非小细胞肺癌患者的脑放射坏死

IF 3.3 3区医学 Q2 ONCOLOGY

Clinical lung cancer Pub Date : 2024-07-02 DOI:10.1016/j.cllc.2024.06.010

Daisuke Shibahara , Kentaro Tanaka , Osamu Togao , Yoshimasa Shiraishi , Yasuto Yoneshima , Eiji Iwama , Tadamasa Yoshitake , Kousei Ishigami , Isamu Okamoto

引用次数: 0

摘要

-11C]蛋氨酸-PET 和 MRS 是诊断脑放射坏死的重要工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Bevacizumab for Brain Radiation Necrosis in Patients With Nonsquamous Nonsmall Cell Lung Cancer

•
The incidence of brain radiation necrosis is increasing in NSCLC patients undergoing radiotherapy for brain metastases.
•
[¹¹C] methionine–PET and MRS are valuable tools for diagnosing brain radiation necrosis.
•
Bevacizumab is an effective treatment for brain radiation necrosis in patients with nonsquamous NSCLC.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical lung cancer 医学-肿瘤学

CiteScore

7.00

自引率

2.80%

发文量

159

审稿时长

24 days

期刊介绍： Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.